CT-868
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 103
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity + T2D | n/r | 26 | n/r | n/r |
| CT-868 1.75 mg | Obesity + T2D | 1.75 mg | 26 | n/r | n/r |
| CT-868 4.0 mg | Obesity + T2D | 4.0 mg | 26 | n/r | n/r |